ARTICLE | Company News
PRCS meets with FDA
September 11, 2001 7:00 AM UTC
Praecis Pharmaceuticals (PRCS) met with FDA in connection with a June 11 letter regarding its injectable Plenaxis abarelix to treat hormonally responsive prostate cancer. According to PRCS, the FDA re...